

**Appendix A-3**  
**Invalidity of U.S. 9,125,739 in View of Bessler and Teitelbaum**

The asserted claims of the '739 patent are anticipated or obvious over United States Patent No. 5,855,601 ("Bessler") and United States Patent No. 5,332,402 ("Teitelbaum"), alone or in combination with the knowledge of a person of ordinary skill in the art at the time of the invention, in combination with one or more other references disclosed in Medtronic's Invalidity Contentions, including other prior art references.

Bessler was filed on June 21, 1996, published on January 5, 1999, so it is prior art under 35 U.S.C. § 102(a), (b), and (c).

The citations provided below are exemplary and do not necessarily include each and every disclosure of the limitations of the asserted claims. Medtronic has endeavored to cite to the most relevant portions of the identified prior art, but other portions may be relevant to the asserted claims, either expressly or inherently, and/or render obvious one or more limitations of the asserted claims. Thus, Medtronic has the right to rely on: (1) uncited portions of the identified prior art; (2) other prior art not identified herein; (3) references to the state of the art (irrespective of whether such references themselves qualify as prior art to the asserted patents); (4) references from the inventors or authors of the prior art references, or purveyors of prior art devices; and/or (5) expert testimony in the context to or aid in understanding the prior art and the state of the art at the time of the alleged invention.

The lack of a citation for an element should not be deemed an admission that the element is not disclosed or is not disclosed by the reference. When the chart indicates a particular reference discloses or embodies a limitation, the terms "discloses," "embodies," and "embodied" refer to explicit and/or inherent disclosure and/or obvious variations of the actual limitation. To the extent Medtronic asserts that a claim is indefinite, Medtronic has used its best efforts to reasonably interpret the claim and perform their duties in charting the prior art references.

Where Medtronic cites to a particular drawing or figure in the accompanying charts, the citation encompasses the drawing or figure, as well as any text associated with the drawing or figure. Similarly, where citations are made to text concerning a drawing or figure, the citation encompasses that drawing or figure. Certain identified prior art inherently disclose features of the asserted claims. Medtronic reserves the right to rely on inherency to demonstrate the invalidity of the asserted claims. Moreover, certain prior art references may inherently disclose certain features of the asserted claims as construed. Medtronic may rely on cited or uncited portions of the prior art, other documents, factual testimony, and expert testimony to demonstrate the inherency of certain features of the prior art to invalidate the asserted claims.

To the extent Colibri contends that the prior art reference does not disclose any particular limitation of the asserted claims, either expressly or inherently, it would have been obvious to a person of ordinary skill in the art as of the time of the invention to modify the reference and/or to combine its teachings with other prior art references, including but not limited to the prior art references identified in Medtronic's invalidity contentions and the relevant sections of the claim charts for the asserted claims in a manner that renders such claims invalid as obvious.

**Appendix A-3**  
**Invalidity of U.S. 9,125,739 in View of Bessler and Teitelbaum**

It would have been obvious under 35 U.S.C. § 103 to a person having ordinary skill in the art at the time of the invention to combine the teachings of Bessler with Teitelbaum, which was filed on May 12, 1992, published or prior art under 35 U.S.C. § 102(a), (b) and (e).

	Claim language	Exemplary disclosure
1.pre	An assembly to treat a native heart valve in a patient, the assembly for use in combination with a guidewire, the assembly comprising:	<p>To the extent this preamble is limiting, Bessler discloses “[a]n assembly to treat a native heart valve in a patient, the assembly for use in combination with a guidewire, the assembly comprising.”</p> <p>For example, Bessler discloses an assembly to treat a native valve in a patient:</p> <p style="padding-left: 40px;">The present invention relates to novel artificial heart valves. More specifically, the present invention relates to novel heart valves that are especially adapted for placement using minimally invasive surgical techniques and a catheter and device useful for such placement.</p> <p>Bessler at col. 1, lines 7-11. Bessler further discloses that the artificial heart valve in combination with a guidewire:</p> <p style="padding-left: 40px;">A guidewire 94 having a blunt end 95 is disposed through a catheter 93 and is used to guide the distal end of the catheter to the desired site.</p> <p>Bessler at col. 7, lines 35-38.</p>
1.a	a prosthetic heart valve including: a stent member having an inner channel, the stent member collapsible, expandable and configured for transluminal percutaneous delivery, wherein	<p>Bessler discloses “a prosthetic heart valve including: a stent member having an inner channel, the stent member collapsible, expandable and configured for percutaneous delivery, wherein.”</p> <p>For example, Bessler discloses an artificial heart valve with a stent member that is collapsible and expandable:</p>


**Appendix A-3**  
**Invalidity of U.S. 9,125,739 in View of Bessler and Teitelbaum**

The invention includes a new heart valve which may be implanted percutaneously and transluminally, which heart valve comprises a stent member and a valve means. The stent member is self-expanding and the valve means that permit flow in only one direction.


Bessler at col. 2, lines 57-62. Bessler further discloses that the artificial heart valve is configured for percutaneous delivery.

The present invention includes methods and devices for implanting a heart valve percutaneously and transluminally. The artificial heart valve of the present invention, which are capable of exhibiting a variable diameter, includes (1) a relatively rigid stent member and (2) a flexible valve means. The stent member is self-expanding and has a first cylindrical shape in its collapsed configuration and a second, larger cylindrical shape in its expanded configuration.

Bessler at col. 3, lines 46-55. The drawings below show the stent member in its collapsed configuration:



**Appendix A-3**  
**Invalidity of U.S. 9,125,739 in View of Bessler and Teitelbaum**


		<p>Bessler at FIG. 4 (showing stent in an expanded configuration).</p>  <p align="right"><b>FIG. 4</b></p> <p>Bessler at FIG. 5 (showing stent in a collapsed configuration).</p>
<p>1.b</p>	<p>the stent member includes a tubular structure away from a central portion that flares at both ends in a trumpet-like configuration; and</p>	<p>The combination of Bessler and U.S. Patent No. 5,332,402 (“Teitelbaum”) teaches a stent member includes a tubular structure away from a central portion that flares at both ends in a trumpet-like configuration; and”</p> <p>For example, Teitelbaum teaches a tubular structure away from a central portion that flares at both ends in a trumpet-like configuration:</p> <p>The percutaneous cardiac valve has two possible designs. The first design consists of two components. In the first design, one of the components is a meshwork of nitinol wire of approximately 0.008 inch gauge. The other component is a tubular structure with a minimum central diameter of 20 mm. In the second design, the tubular structure flares markedly at both ends in a trumpet-like configuration. The maximum longitudinal dimension of the tubular structure which shall be referred to as the stent or doubly-flared stent is 20 mm. The maximum diameter of the flared ends of the stent is 30 mm. The purpose of the stent is to maintain a semi-rigid structure through the diseased cardiac valve following its balloon dilatation.</p>

**Appendix A-3**  
**Invalidity of U.S. 9,125,739 in View of Bessler and Teitelbaum**

ends of the stent maintain the position of this component valve following deployment. The stent contains a thin h coating that helps prevent thrombus formation along the in stent.

Teitelbaum at col. 2, lines 21-39.

**FIG. 2**



Teitelbaum at FIG. 2.

Both Bessler and Teitelbaum recognize the desirability of “anchor[ing] a member at a desired site” Bessler at col. 2, lines 62-63). Bessler teaches the use of barbs to aid in achieving this goal (id.). Teitelbaum explains that the purpose of the stent is to “maintain the position of this component across the native vessel during deployment” Teitelbaum at col. 2, lines 34-36 and col. 5, lines 63-66.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.